🇺🇸 FDA
Pipeline program

QR-1123

PQ-1123-001

Phase 2 small_molecule active

Quick answer

QR-1123 for Autosomal Dominant Retinitis Pigmentosa is a Phase 2 program (small_molecule) at ProQR Therapeutics N.V. with 1 ClinicalTrials.gov record(s).

Program details

Company
ProQR Therapeutics N.V.
Indication
Autosomal Dominant Retinitis Pigmentosa
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials